
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Imaging, Diagnosis, Prognosis |
Authors' Affiliations: 1 Genomics Group, Wellcome Trust Centre for Human Genetics, The Henry Wellcome Building for Genomic Medicine, University of Oxford, 2 Oxygen Sensing Group, The Henry Wellcome Building for Molecular Physiology, University of Oxford, 3 Cancer Research UK Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom, and 4 Department of Medical Oncology, Institut Jules Bordet, Université Libre de Bruxelles, Belgium
Requests for reprints: Jiannis Ragoussis, Genomics Group, Wellcome Trust Centre for Human Genetics, The Henry Wellcome Building for Genomic Medicine, University of Oxford, Oxford OX3 7BN, United Kingdom. E-mail: ioannis.ragoussis{at}well.ox.ac.uk.
Purpose: MicroRNA (miRNA) expression alterations have been described in cancer. Many cancers are characterized by areas of hypoxia, enhanced hypoxia-inducible factor (HIF) levels, and increased expression of hypoxically regulated genes, all of which correlate with patient outcome. We examined hypoxia-induced miRNA expression changes to identify markers of survival in breast cancer.
Experimental Design: We used microarrays to analyze miRNA expression changes induced by hypoxia in MCF7 breast cancer cell lines and validated results by quantitative-PCR (Q-PCR). Small interfering RNA against HIF-1
and HIF-2
, and RCC4 cells transfected with the von Hippel-Lindau (VHL) protein were used to investigate HIF dependency of miRNA expression. miRNA Q-PCR assays were done on 219 early breast cancer samples with long-term follow-up. Correlation of expression with clinical variables was done using Pearson and Spearman's rank tests, univariate, and Cox multivariate analysis.
Results: hsa-miR-210 induction was the most significant change under hypoxia by microarray analysis (3.4-fold, P < 0.001). hsa-miR-210 expression changes were validated by Q-PCR and detected in other cancer cell lines. Using small interfering RNAs and RCC4 cells transfected with VHL, we showed that the regulation by hypoxia of hsa-miR-210 was mediated by the HIF-1
/VHL transcriptional system but not HIF-2
. hsa-miR-210 expression levels in breast cancer samples correlated directly with a hypoxia score based on the expression of 99 genes. hsa-miR-210 expression levels showed an inverse correlation with disease-free and overall survival, significant in both univariate and multivariate analyses.
Conclusions: We show that hsa-miR-210 overexpression is induced by hypoxia in a HIF-1
– and VHL-dependent fashion and its expression levels in breast cancer samples are an independent prognostic factor.
This article has been cited by other articles:
![]() |
Q.-T. X. Le, J. Moon, M. Redman, S. K. Williamson, P. N. Lara Jr, Z. Goldberg, L. E. Gaspar, J. J. Crowley, D. F. Moore Jr, and D. R. Gandara Phase II Study of Tirapazamine, Cisplatin, and Etoposide and Concurrent Thoracic Radiotherapy for Limited-Stage Small-Cell Lung Cancer: SWOG 0222 J. Clin. Oncol., June 20, 2009; 27(18): 3014 - 3019. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. R. Mole, C. Blancher, R. R. Copley, P. J. Pollard, J. M. Gleadle, J. Ragoussis, and P. J. Ratcliffe Genome-wide Association of Hypoxia-inducible Factor (HIF)-1{alpha} and HIF-2{alpha} DNA Binding with Expression Profiling of Hypoxia-inducible Transcripts J. Biol. Chem., June 19, 2009; 284(25): 16767 - 16775. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Li, H. Huang, L. Sun, M. Yang, C. Pan, W. Chen, D. Wu, Z. Lin, C. Zeng, Y. Yao, et al. MiR-21 Indicates Poor Prognosis in Tongue Squamous Cell Carcinomas as an Apoptosis Inhibitor Clin. Cancer Res., June 15, 2009; 15(12): 3998 - 4008. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Gentner and L. Naldini Tissue-Specific MicroRNAs and Regulation of the Tumor Microenvironments Am. Assoc. Cancer Res. Educ. Book, April 18, 2009; 2009(1): 159 - 162. [Full Text] [PDF] |
||||
![]() |
X. Wang A PCR-based platform for microRNA expression profiling studies RNA, April 1, 2009; 15(4): 716 - 723. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. E. Crosby, R. Kulshreshtha, M. Ivan, and P. M. Glazer MicroRNA Regulation of DNA Repair Gene Expression in Hypoxic Stress Cancer Res., February 1, 2009; 69(3): 1221 - 1229. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Foekens, A. M. Sieuwerts, M. Smid, M. P. Look, V. de Weerd, A. W. M. Boersma, J. G. M. Klijn, E. A. C. Wiemer, and J. W. M. Martens Four miRNAs associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer PNAS, September 2, 2008; 105(35): 13021 - 13026. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Fasanaro, Y. D'Alessandra, V. Di Stefano, R. Melchionna, S. Romani, G. Pompilio, M. C. Capogrossi, and F. Martelli MicroRNA-210 Modulates Endothelial Cell Response to Hypoxia and Inhibits the Receptor Tyrosine Kinase Ligand Ephrin-A3 J. Biol. Chem., June 6, 2008; 283(23): 15878 - 15883. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |